Gargling salt water is a time-tested way to alleviate sore-throat pain. As a nasal lavage, it can help clear stuffy sinuses associated with colds and allergies. But, is gargling salt water effective against the symptoms of COVID-19?
An article raising concern about the safety of using hydroxychloroquine as a treatment of COVID-19 that forced the World Health Organization to temporarily suspend a clinical study involving the drug was retracted.
Myovant announced additional data from the company’s Phase III HERO trial of once-daily, oral relugolix in advanced prostate cancer.
A protein called ACE2 is intimately involved in how SARS-CoV-2, the virus that causes COVID-19, infects the body.
As the mortality figures for COVID-19 continued to rise, people are wondering where they will stop. The actual death toll for COVID-19 will not be calculable for some time, but there are early indications that the mortality rate may be significantly lower than calculations of deaths per confirmed cases lead one to believe.
A review of some recently published scientific studies, including researchers at the University of Maryland Baltimore County identifying a single nucleotide that controls two forms of the HIV virus’ RNA.
Incyte announced that data from the Phase 3 REACH2 study were published in The New England Journal of Medicine demonstrating that ruxolitinib – marketed in the United States as Jakafi – improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GVHD) compared to best available therapy.
Although not official and largely anecdotal, there are early signs that Gilead Sciences’ experimental antiviral drug remdesivir is effective in treating COVID-19.
Gilead Sciences Inc.’s shares surged 16 percent in after-hours trading on Thursday following a media report detailing encouraging partial data from trials of the U.S. company’s experimental drug remdesivir in severe COVID-19 patients.
Sunovion Pharmaceuticals Inc. announced that results of a four-week pivotal study (SEP361-201) evaluating the safety and efficacy of SEP-363856 in patients with schizophrenia were published online in the New England Journal of Medicine.